MVA PvDBP

MVA PvDBP is a viral-vectored vaccine candidate for the prevention of Plasmodium vivax malaria. It uses the Modified Vaccinia Ankara (MVA) virus as a vector to deliver the gene encoding region II of the Plasmodium vivax Duffy Binding Protein (PvDBPII), a key protein involved in parasite invasion of human reticulocytes. The vaccine is designed to induce immune responses—both antibody and T cell mediated—against PvDBPII, thereby inhibiting parasite entry into red blood cells and reducing blood-stage parasitemia. In clinical trials, MVA PvDBP has been administered as part of a heterologous prime-boost regimen with ChAd63 PvDBP or alone as a booster. The vaccine has demonstrated safety and immunogenicity in healthy adults and induced functional antibodies capable of inhibiting binding between PvDBPII and its receptor on red blood cells[2][3][6][7][8]. Development is led by academic groups including the Jenner Institute at University of Oxford.

Other names

Modified Vaccinia Ankara PvDBPMVA-PvDBPIIMVA-PvDBP_RII